Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) released its earnings results on Monday. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.12), Zacks reports. The business had revenue of ($1.78) million for the quarter, compared to the consensus estimate of $7.53 million. Verrica Pharmaceuticals had a negative return on equity of 591.84% and a negative net margin of 625.06%.
Verrica Pharmaceuticals Stock Performance
Shares of NASDAQ:VRCA traded down $0.63 during midday trading on Tuesday, reaching $0.80. 3,679,848 shares of the company traded hands, compared to its average volume of 448,386. The company has a quick ratio of 2.23, a current ratio of 2.36 and a debt-to-equity ratio of 29.58. Verrica Pharmaceuticals has a 12 month low of $0.75 and a 12 month high of $11.41. The firm has a market capitalization of $34.03 million, a price-to-earnings ratio of -0.42 and a beta of 1.45. The firm's fifty day moving average price is $1.71 and its two-hundred day moving average price is $5.21.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on the stock. Royal Bank of Canada cut shares of Verrica Pharmaceuticals from an "outperform" rating to a "sector perform" rating and dropped their target price for the company from $11.00 to $2.00 in a research note on Tuesday. Needham & Company LLC reissued a "hold" rating on shares of Verrica Pharmaceuticals in a research report on Tuesday. Brookline Capital Management reaffirmed a "hold" rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, October 2nd. Finally, TD Cowen lowered their price objective on Verrica Pharmaceuticals from $15.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, October 21st. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Verrica Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus price target of $9.60.
Check Out Our Latest Stock Analysis on VRCA
About Verrica Pharmaceuticals
(
Get Free Report)
Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.
Further Reading
Before you consider Verrica Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verrica Pharmaceuticals wasn't on the list.
While Verrica Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
